Cleland, J. G.F. (2024) Nature and magnitude of the benefits of dapagliflozin and empagliflozin for heart failure. Circulation, 149(11), pp. 839-842. (doi: 10.1161/circulationaha.123.068089) (PMID:38466791)
![[img]](https://cdn.statically.io/img/eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
323100.pdf - Accepted Version Restricted to Repository staff only until 11 September 2024. 197kB |
Abstract
No abstract available.
| Item Type: | Articles (Editorial) |
|---|---|
| Keywords: | Physiology (medical), Cardiology and Cardiovascular Medicine |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Cleland, Professor John |
| Authors: | Cleland, J. G.F. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
| Journal Name: | Circulation |
| Publisher: | Lippincott, Williams and Wilkins for American Heart Association |
| ISSN: | 0009-7322 |
| ISSN (Online): | 1524-4539 |
| Published Online: | 11 March 2024 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details